All In MedTech

Device Trial Radar · NCT06915922

YAG Laser Vitreolysis for Vitreous Floaters

Therapeutic Neodymium-doped Yttrium-Aluminum-Garnet (Nd:YAG) Laser Vitreolysis for Vitreous Floaters - A Study to Quantify Visual Quality of Life, Vitreous Structure, and Vision Before and After Nd:YAG Laser Vitreolysis in Patients With Vision Degrading Myodesopsia

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Oct 17, 2023

Primary completion

Aug 13, 2026

Study completion Aug 13, 2026

Sponsor

Lead sponsor
VMR Consulting, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Retina Clinic - London Ophthalmic Institute
First posted
Apr 8, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters". In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.

Conditions

  • Posterior Vitreous Detachment
  • Myopic Vitreopathy
  • VISION DEGRADING MYODESOPSIA

Interventions

  • Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapyDevice

    Nd:YAG laser treatment(s) for Vision Degrading Myodesopsia (clinically significant vitreous floaters) in eyes with vitreous opacities due to myopic vitreopathy and posterior vitreous detachment (PVD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measures of vitreous structure by quantitative ultrasonographyTime frame: baseline, 3 months, 6 months, 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VMR Institute for Vitreous Macula Retina

    Huntington Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.